RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $9.50 Consensus Target Price from Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has earned an average rating of “Hold” from the thirteen analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, ten have given a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $9.50.

RAPT has been the topic of a number of research reports. Stifel Nicolaus reissued a “hold” rating and issued a $2.00 price objective (down previously from $7.00) on shares of RAPT Therapeutics in a report on Wednesday, November 13th. Piper Sandler lowered RAPT Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $8.00 to $2.00 in a research note on Monday, November 11th. JPMorgan Chase & Co. downgraded RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, November 11th. Wells Fargo & Company reduced their price target on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research report on Tuesday, November 12th. Finally, UBS Group lowered their price objective on RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating on the stock in a research report on Monday, September 9th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC bought a new stake in shares of RAPT Therapeutics in the 1st quarter worth about $97,000. EntryPoint Capital LLC purchased a new position in shares of RAPT Therapeutics during the first quarter valued at approximately $161,000. Readystate Asset Management LP purchased a new position in shares of RAPT Therapeutics during the third quarter valued at approximately $36,000. XTX Topco Ltd purchased a new stake in shares of RAPT Therapeutics in the second quarter worth approximately $108,000. Finally, Barclays PLC lifted its stake in shares of RAPT Therapeutics by 277.2% during the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after acquiring an additional 29,195 shares during the last quarter. 99.09% of the stock is owned by hedge funds and other institutional investors.

RAPT Therapeutics Trading Down 3.3 %

Shares of RAPT opened at $1.04 on Friday. The firm has a fifty day simple moving average of $1.86 and a two-hundred day simple moving average of $2.80. The firm has a market cap of $36.18 million, a PE ratio of -0.37 and a beta of 0.33. RAPT Therapeutics has a 1-year low of $1.00 and a 1-year high of $27.35.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.09. As a group, research analysts forecast that RAPT Therapeutics will post -2.8 EPS for the current fiscal year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.